Clinical trial · no report yet · Phase 1
BEHOLD-1
A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1)
- NCT06431594 ↗
- Recruiting
- GlaxoSmithKline
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 3 | |
| Podcasts | 2 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Subjects With Advanced Solid Tumors
- Phase
- Phase 1
- Status
- Recruiting
- Conditions
- Solid Tumors; Neoplasms
- Interventions
- Mocertatug rezetecan
- Arms
- Part 1: Dose Escalation · Experimental
- Part 2: Dose Expansion · Experimental
- Enrollment
- 675 (estimated)
- Primary outcomes
- Part 1: Number of participants with dose limiting toxicity (DLT)
- Part 2-Confirmed Objective Response Rate (ORR) assessed by investigator
- Sponsor
- GlaxoSmithKline
- Start
- Jul 2, 2024
- Primary completion
- Sep 22, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT06431594 · updated Jun 25, 2026
Publications
linked from the registry- Lheureux S, Provencher D, Baka S, Kowalyszyn R, Schutte T, Urun Y, Zeng X, Oaknin A, Lorusso D, Ray-Coquard I, Moreno V, Jalkanen K, Liu Burstrom L, van Dongen MGJ, Boni V, Lee JY, Bedard PL, Malinowska IA, Kaisermann M, McKean W. BEHOLD-1 and -2: phase 1/2 randomized studies evaluating the B7 homolog 4 protein-targeted antibody-drug conjugate mocertatug rezetecan in patients with solid tumors, including endometrial and ovarian cancers. Int J Gynecol Cancer. 2026 Sep 7:105607. doi: 10.1016/j.ijgc.2026.105607. Online ahead of print. PubMed 42850140